Abstract
Several natural compounds containing an anthraquinone core linked to a prenyloxy chain have been reported in the literature in recent years. The discovery in the plant kingdom of such secondary metabolites is a novel acquisition in the phytochemistry research field and in many cases led to a re-consideration of the secondary metabolite pool of well known anthraquinone-containing plants. In this review article we will focus on the phytochemistry and pharmacognosy of prenyloxyanthraquinones putting in evidence the natural sources and their biological properties as anti-microbial and anticancer agents.
Keywords: Anthraquinones, anti-cancer activity, anti-inflammatory activity, oxyprenylated seconddary metabolites, polyketides.
Current Drug Targets
Title:Phytochemistry and Pharmacognosy of Naturally Occurring Prenyloxyanthraquinones
Volume: 14 Issue: 9
Author(s): Francesco Epifano, Serena Fiorito, Giuseppe Carlucci, Marcello Locatelli and Salvatore Genovese
Affiliation:
Keywords: Anthraquinones, anti-cancer activity, anti-inflammatory activity, oxyprenylated seconddary metabolites, polyketides.
Abstract: Several natural compounds containing an anthraquinone core linked to a prenyloxy chain have been reported in the literature in recent years. The discovery in the plant kingdom of such secondary metabolites is a novel acquisition in the phytochemistry research field and in many cases led to a re-consideration of the secondary metabolite pool of well known anthraquinone-containing plants. In this review article we will focus on the phytochemistry and pharmacognosy of prenyloxyanthraquinones putting in evidence the natural sources and their biological properties as anti-microbial and anticancer agents.
Export Options
About this article
Cite this article as:
Epifano Francesco, Fiorito Serena, Carlucci Giuseppe, Locatelli Marcello and Genovese Salvatore, Phytochemistry and Pharmacognosy of Naturally Occurring Prenyloxyanthraquinones, Current Drug Targets 2013; 14(9) . https://dx.doi.org/10.2174/1389450111314090004
DOI https://dx.doi.org/10.2174/1389450111314090004 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Pleiotropic Effect of Mahanine and Girinimbine Analogs: Anticancer Mechanism and its Therapeutic Versatility
Anti-Cancer Agents in Medicinal Chemistry Viral Vectors for Gene-Directed Enzyme Prodrug Therapy
Current Gene Therapy Emerging Treatments in Acute Lymphoblastic Leukemia
Current Cancer Drug Targets Neuroprotective Gene Therapy for the Treatment of Inherited Retinal Degeneration
Current Gene Therapy Emerging Roles of P2X Receptors in Cancer
Current Medicinal Chemistry Ellipticines as DNA-Targeted Chemotherapeutics
Current Medicinal Chemistry Advances in Stem Cell Therapy for Leukemia
Current Stem Cell Research & Therapy Tackling COVID-19 Through Ayurveda: A Review on the Herbs of Recommended Indian Remedies
Current Traditional Medicine Aging and Inflammation: Etiological Culprits of Cancer
Current Aging Science Cytisine - From the Past to the Future
Current Pharmaceutical Design N6-Isopentenyladenosine and its Analogue N6-Benzyladenosine Induce Cell Cycle Arrest and Apoptosis in Bladder Carcinoma T24 Cells
Anti-Cancer Agents in Medicinal Chemistry Regulation and Function of DNA and Histone Methylations
Current Pharmaceutical Design New Perspective on the Dual Functions of Indirubins in Cancer Therapy and Neuroprotection
Anti-Cancer Agents in Medicinal Chemistry Epidermal Growth Factor Receptor Inhibitors: A New Prospective in the Treatment of Lung Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective
Current Pharmaceutical Design Beyond Oncolytic Virotherapy: Replication-Competent Retrovirus Vectors for Selective and Stable Transduction of Tumors
Current Gene Therapy Apoptosis Suppression by Candidate Oncogene PLAC8 is Reversed in Other Cell Types
Current Cancer Drug Targets Targeting Schistosome Histone Modifying Enzymes for Drug Development
Current Pharmaceutical Design Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC)
Current Drug Targets Bladder Cancer: A Simple Model Becomes Complex
Current Genomics